2 1 Shi Ji Jing Ji Bao Dao·2025-04-30 02:02Group 1 - The Hong Kong innovative drug sector showed strength with the Hong Kong Innovative Drug ETF (159567) rising over 1.20% and trading volume exceeding 1 billion yuan, with a turnover rate above 8% [1] - Key stocks such as BeiGene rose over 6%, along with other companies like Rongchang Bio, CanSino Biologics, and CSPC Pharmaceutical [1] - The Hong Kong Innovative Drug ETF closely tracks the Hong Kong Stock Connect Innovative Drug Index (987018), reflecting the operational characteristics of listed biotech companies in Hong Kong [1] Group 2 - China Galaxy Securities reported that the pharmaceutical sector has undergone a prolonged adjustment, with overall valuations at low levels and public fund holdings underweight, indicating potential marginal improvement in payment under supportive policies for commercial insurance by 2025 [2] - The report suggests that the innovative drug and device sectors are likely to benefit, with a continuous recovery in the pharmaceutical market and structural opportunities remaining [2] - Huafu Securities noted that the first quarter revealed a consensus on increasing positions in innovative drugs, highlighting a significant bottom reversal trend in the pharmaceutical sector after four years of adjustment [2]